Committee-Grade Evidence: Preparing UK MedComms Materials for Formulary and Pathway Decisions

A clinical story can be scientifically sound and still fall flat in an NHS formulary or pathway committee. The reason is rarely the quality of the underlying evidence. More often, the material has been written for clinicians in a promotional or educational setting, while the committee is trying to make a commissioning, prescribing or pathway decision. Those are different reading tasks, and they demand different writing.

For UK medical communications teams, the opportunity is to act as translators rather than advocates. Committee members may include pharmacists, consultants, GP representatives, medicines optimisation leads, finance colleagues and commissioning managers. They need to see what is being proposed, for which patients, compared with what, on what evidence, with what uncertainty and with what practical consequences for local services. Promotional gloss does not help them reach a defensible decision; clear, referenced and proportionate evidence does.

Start with the decision, not the disease

Before drafting a single section, establish the decision the committee is being asked to take. Is it whether to add a treatment to the formulary, restrict it to a defined cohort, approve a pathway change, support a switch, or simply note updated guidance? Each decision requires a different emphasis. A formulary addition may need comparative effectiveness and place in therapy; a pathway change may need service implications and implementation detail; a restricted-use proposal may need precise eligibility criteria and stopping rules.

MedComms teams should ask the client for the committee remit, submission template, page limits and any published minutes or decision records that show how previous submissions were assessed. This is not administrative detail. It determines the shape of the evidence story. A useful discipline is to write the decision question at the top of the drafting file and test every section against it. If a paragraph does not help the committee answer that question, it probably belongs in a background document rather than the core pack.

From value proposition to decision proposition

Commercial value propositions tend to foreground differentiation. Committee propositions need to foreground relevance. A more useful formulation is: for this patient group, compared with this alternative, the intervention produces this outcome, with this level of certainty, and here is what that means for local implementation.

That shift does not require the team to diminish the evidence. It requires the evidence to be stated in a form the committee can use. Avoid bare claims of superiority where the trial was not designed to test superiority against the relevant local comparator. Distinguish clearly between licensed indications and anticipated use. Where the evidence is indirect, say so. Where the effect is statistically significant but of uncertain clinical importance, say that too. A short 'what this means for the committee' box can be more valuable than another page of mechanism.

Build an evidence summary that bears scrutiny

Committee packs benefit from structured evidence tables rather than narrative summaries alone. A workable table records the study, design, population, comparator, endpoints, key results, limitations and relevance to the decision. Absolute effects should be presented alongside relative effects where appropriate, with denominators and time horizons stated. Consistency matters: the same number should appear in the summary, the slide deck and the appendix, or the committee will reasonably question the whole submission.

Reference every substantive claim to an approved source and check that the source is current. If the pack draws on NICE guidance, Scottish Medicines Consortium advice, local prescribing guidance or published real-world evidence, represent that material accurately and note its date. Do not silently update a figure or omit a limitation because it weakens the case. Committees are used to reading evidence critically, and an omission is more damaging than a candid caveat.

Place the evidence in the NHS context

A committee is not only asking whether a product works. It is asking how it would work here. That means describing the patient pathway: where the intervention sits, what diagnosis or monitoring is required, who would initiate it, what stopping criteria apply and what service capacity it assumes. Use NHS language carefully and accurately. References to integrated care boards, trusts, formularies, area prescribing committees, medicines optimisation and pathway redesign should reflect how those bodies actually operate. Remember that arrangements differ across England, Scotland, Wales and Northern Ireland; a single UK-wide template may need local adaptation fields.

Budget impact is often part of the committee's concern, but MedComms teams should not improvise health economics. If cost figures are included, they must be sourced, approved and clearly labelled. If they are outside scope, the pack can still acknowledge implementation considerations without making unsupported financial claims. The aim is to help the committee see the practical consequences, not to pretend that uncertainty has been removed.

Make plain-language appendices do real work

Plain-language appendices are not a simplified afterthought. They are often the section that helps non-specialist members engage with the evidence. Define acronyms, explain what a hazard ratio or confidence interval means in ordinary terms, summarise eligibility and monitoring requirements, and include a short glossary. Keep sentences short and headings descriptive. Avoid patronising the reader; the goal is clarity, not dilution.

Any plain-language summary must remain consistent with the approved summary of product characteristics and the reviewed materials. It should not introduce new claims or imply a broader use than the evidence supports. Accessibility also matters: clear document structure, readable fonts, meaningful headings and alt text for figures all help committee members who read on screen or use assistive technology.

Keep compliance visible throughout

Committee submissions may be non-promotional in intent, but they remain subject to the relevant company procedures and the ABPI Code, as well as applicable regulatory requirements. Medical, regulatory, legal and compliance review should be planned into the timeline rather than bolted on at the end. Version control, reference packs, approval records and confidentiality markings all need to be in place before the pack leaves the team. If patient stories or patient-level data are used, data protection and consent arrangements must be clear.

A pre-submission checklist for MedComms teams

• Confirm the committee, its remit and the exact decision being sought.
• Check the template, page limits, submission deadline and local variation requirements.
• Write the decision question at the top of the pack and test every section against it.
• Verify that every substantive claim is referenced to an approved, current source.
• Check numerical consistency across summary, tables, slides and appendices.
• Present absolute and relative effects with denominators and time horizons.
• State limitations, evidence gaps and uncertainties plainly.
• Represent NICE, SMC and local guidance accurately, with dates where relevant.
• Describe pathway fit and service implications without unsupported assumptions.
• Source and approve any budget impact figures, or omit them.
• Include a glossary, acronym list and plain-language explanation of key endpoints.
• Complete medical, regulatory, legal and compliance review and record certification.
• Apply confidentiality markings and data-sharing rules correctly.
• Check accessibility, version control and a named contact for queries.
• Run a short internal dry run against the committee's likely questions.

Committee-ready writing is not a softer version of medical communications. It is a more disciplined form of it. The science remains intact, but it is organised around a decision rather than a message. For UK MedComms teams, that discipline is a genuine professional contribution: helping clients present evidence honestly, contextually and in a form that NHS decision-makers can actually use.